GR-MD-02

Phase 2Small molecule

GGalectin Therapeutics Inc.

GR-MD-02 is one of 193 small molecule programs targeting Portal Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

192

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal HypertensionActive, not recruiting

FibrosisActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

PsoriasisActive, not recruiting

Portal HypertensionPhase 2

Active, not recruiting

FibrosisPhase 2

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

GR-MD-02

GGalectin Therapeutics Inc.

Phase 2

1 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Imjudo

AstraZeneca

Preclinical

5 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

Remeron

OOrganon and Co

Preclinical

1 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

REGN2810

Regeneron

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fibrosis1 trial

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Completed·GGalectin Therapeutics Inc.·Phase 2·NCT02421094·30 enrolled

Melanoma1 trial

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Withdrawn·PProvidence Health & Services·Phase 2·NCT04987996

Psoriasis1 trial

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

Completed·GGalectin Therapeutics Inc.·Phase 2·NCT02407041·5 enrolled

Non-Alcoholic Steatohepatitis1 trial

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Completed·GGalectin Therapeutics Inc.·Phase 1·NCT01899859·31 enrolled

Portal Hypertension1 trial

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Completed·GGalectin Therapeutics Inc.·Phase 2·NCT02462967·162 enrolled

1 more indication

Non-Small Cell Lung Cancer1 trial

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Completed·PProvidence Health & Services·Phase 1·NCT02575404·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for GR-MD-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GR-MD-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GR-MD-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Galectin Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGalectin Therapeutics Inc.

GR-MD-02

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fibrosis1 trial

Melanoma1 trial

Psoriasis1 trial

Non-Alcoholic Steatohepatitis1 trial

Portal Hypertension1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News